yf_tkr_NVS · 2026-10-20
PBYI raised its 2026 Nerlynx sales outlook after 3.5% first-half 2026 growth, with Q3 revenues expected to reach $54-$56 million.
Sector coverage: Healthcare · Biotechnology · Drug Manufacturers - General
Read the original at yf_tkr_NVS ↗
Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.
Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。